NFJ Investment Group LLC Trims Position in LivaNova PLC $LIVN

NFJ Investment Group LLC decreased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 21.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,170 shares of the company’s stock after selling 10,999 shares during the quarter. NFJ Investment Group LLC’s holdings in LivaNova were worth $2,533,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Hantz Financial Services Inc. grew its holdings in shares of LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares in the last quarter. State of Wyoming purchased a new position in shares of LivaNova during the second quarter worth about $31,000. EverSource Wealth Advisors LLC grew its holdings in shares of LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares in the last quarter. Quarry LP purchased a new position in shares of LivaNova during the third quarter worth about $36,000. Finally, Covestor Ltd grew its holdings in shares of LivaNova by 108.6% during the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after purchasing an additional 392 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on LIVN shares. Needham & Company LLC boosted their price objective on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Robert W. Baird cut their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Mizuho boosted their price objective on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Barclays boosted their price objective on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Finally, Piper Sandler reissued an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a report on Thursday, February 19th. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $79.38.

LivaNova Price Performance

Shares of LIVN opened at $79.39 on Monday. The firm has a market cap of $4.36 billion, a P/E ratio of 40.71 and a beta of 0.88. The stock has a 50 day simple moving average of $69.08 and a two-hundred day simple moving average of $65.81. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. LivaNova PLC has a 1 year low of $41.01 and a 1 year high of $80.74.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.13. The business had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.LivaNova’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, analysts forecast that LivaNova PLC will post 3.73 earnings per share for the current fiscal year.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the sale, the director owned 7,228 shares of the company’s stock, valued at $547,521. This represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.35% of the stock is currently owned by corporate insiders.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.